VRPX · Virpax Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| R&D | $5.82M | $5.12M | $10.76M | $1.29M |
| SG&A | $6.26M | $10.57M | $11.08M | $2.90M |
| Total Operating Expenses | $12.08M | $15.69M | $21.85M | $4.20M |
| D&A | - | - | - | - |
| Operating Income | ($12.08M) | ($15.69M) | ($21.85M) | ($4.20M) |
| Interest Expense | $103.8K | - | - | $147.9K |
| Income Tax | - | - | - | - |
| Net Income | ($12.07M) | ($15.19M) | ($21.65M) | ($4.34M) |
| EPS - Basic | ($71.00) | ($324.25) | ($462.50) | ($350.00) |
| EPS - Diluted | ($71.00) | ($324.25) | ($452.50) | - |
Balance Sheet
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash & Equivalents | $1.51M | $9.14M | $19.00M | $41.5K |
| Accounts Receivable | - | - | - | - |
| Inventory | - | - | - | - |
| Accounts Payable | - | - | - | - |
| Current Assets | $1.56M | $9.63M | $19.67M | $39.57M |
| Total Assets | $1.56M | $9.63M | $19.67M | $39.57M |
| Current Liabilities | $2.47M | $7.69M | $3.09M | $2.09M |
| Long-term Debt | - | - | - | - |
| Total Liabilities | $2.47M | $7.69M | $3.09M | $2.09M |
| Stockholders' Equity | ($913.8K) | $1.93M | $16.58M | $37.48M |
| Retained Earnings | ($71.61M) | ($59.54M) | ($44.35M) | ($22.70M) |
Cash Flow
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Operating Cash Flow | ($16.71M) | ($9.85M) | ($17.85M) | ($1.38M) |
| Investing Cash Flow | - | - | - | - |
| Financing Cash Flow | $9.08M | - | - | $1.40M |
| CapEx | - | - | - | - |
| Free Cash Flow | - | - | - | - |
Ratios
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Profitability | ||||
| Gross margin | - | - | - | - |
| Operating margin | - | - | - | - |
| EBITDA margin | - | - | - | - |
| Net margin | - | - | - | - |
| Free cash flow margin | - | - | - | - |
| FCF / Net income | - | - | - | - |
| R&D / Revenue | - | - | - | - |
| SG&A / Revenue | - | - | - | - |
| Effective tax rate | - | - | - | - |
| Return on assets | -775.7% | -157.8% | -110.0% | -11.0% |
| Return on equity | 1320.6% | -785.3% | -130.6% | -11.6% |
| Return on invested capital | - | - | - | - |
| Liquidity | ||||
| Current ratio | 0.63 | 1.25 | 6.36 | 18.96 |
| Quick ratio | 0.63 | 1.25 | 6.36 | 18.96 |
| Cash ratio | 0.61 | 1.19 | 6.14 | 0.02 |
| Leverage | ||||
| Debt / Equity | - | - | - | - |
| Debt / Assets | - | - | - | - |
| Debt / EBITDA | - | - | - | - |
| Interest coverage | -116.4x | - | - | -28.4x |
| Equity multiplier | -1.70 | 4.98 | 1.19 | 1.06 |
| Liabilities / Assets | 1.59 | 0.80 | 0.16 | 0.05 |
| Efficiency | ||||
| Asset turnover | - | - | - | - |
| Inventory turnover | - | - | - | - |
| Days sales outstanding | - | - | - | - |
| Days inventory outstanding | - | - | - | - |
| Days payable outstanding | - | - | - | - |
| Cash conversion cycle | - | - | - | - |
| Valuation | ||||
| P / E | - | - | - | - |
| P / B | - | 48.5x | 62.7x | - |
| P / S | - | - | - | - |
| EV / EBITDA | - | - | - | - |
| Growth | ||||
| Revenue growth (YoY) | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - |
| Operating income growth (YoY) | 23.0% | 28.2% | -420.7% | - |
| Net income growth (YoY) | 20.6% | 29.8% | -398.9% | - |
| EPS growth (YoY) | 78.1% | 28.3% | - | - |
| EPS CAGR (3y) | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - |
| FCF growth (YoY) | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - |
| Book value growth (YoY) | - | -88.3% | -55.8% | - |
Stability scores
Piotroski F-score
FY 2024 · 9-point quality
0/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Virpax Pharmaceuticals against the 5 most active filers in the same SIC group.